期刊文献+

老年肺癌并发静脉血栓形成患者血清miR-374a-5p、miR-200c-3p、SAA4表达水平及检测意义 被引量:1

The expression levels and detection significance of serum miR-374a-5p,miR-200c-3p,and SAA4 in elderly lung cancer patients with VTE
暂未订购
导出
摘要 目的探究血清微小RNA(miR)-374a-5p、微小RNA(miR)-200c-3p、淀粉样蛋白A(SAA)4在老年肺癌并发静脉血栓形成(VTE)患者中的表达及检测意义。方法选取2021年2月-2023年11月广安市人民医院收治的154例肺癌患者为研究对象,根据化疗后VTE发生情况分为VTE组(n=33)和非VTE组(n=121)。实时荧光定量(RT-PCR)检测血清miR-374a-5p和miR-200c-3p;ELISA检测血清SAA4。多因素Logistic回归分析老年肺癌患者VTE的影响因素;ROC曲线分析血清miR-374a-5p、miR-200c-3p、SAA4对老年肺癌患者VTE的预测价值。结果154例中,共有33例发生VTE,发生率为21.43%。与非VTE组比较,VTE组合并糖尿病占比均明显较高(χ^(2)=5.866,P<0.05)。与非VTE组比较,VTE组血清miR-374a-5p、miR-200c-3p、SAA4水平显著较高(t=9.143、5.538、6.243,P<0.05)。多因素Logistic回归结果显示,合并糖尿病(OR=1.851)、血清miR-374a-5p(OR=1.584)、miR-200c-3p(OR=1.519)、SAA4水平(OR=1.627)为老年肺癌患者VTE的危险因素(P<0.05)。ROC曲线显示,血清miR-374a-5p、miR-200c-3p、SAA4单独预测老年肺癌患者VTE的AUC分别为0.746、0.770和0.748,敏感度分别为72.73%、66.67%和75.76%,特异度分别为83.47%、84.30%和82.64%;三者联合预测老年肺癌患者VTE的AUC为0.910,敏感度为87.50%,特异度为80.90%。结论老年肺癌并发VTE患者血清miR-374a-5p、miR-200c-3p、SAA4水平较高,且血清miR-374a-5p、miR-200c-3p、SAA4联合预测老年肺癌患者VTE的价值较高,有助于临床预测。 Objective To investigate the expression and detection significance of serum microRNA-374a-5p,microRNA-200c-3p,and serum amyloid A4(SAA4)in elderly patients with lung cancer complicated with venous thromboembolism(VTE).Methods A total of 154 patients with lung cancer admitted to Guang'an People's Hospital from February 2021 to November 2023 were selected as the study objects.According to the incidence of VTE after chemotherapy,they were divided into VTE group(n=33)and non-VTE group(n=121).Real-time fluorescence quantification(RT-PCR)was applied to detect serum mi-374a-5p and miR-200c-3p.ELISA was applied to detect serum SAA4.Multivariate logistic regression was applied to analyze the influencing factors of VTE in elderly lung cancer patients.ROC curve was applied to analyze the predictive value of serum miR-374a-5p,miR-200c-3p,and SAA4 for VTE in elderly lung cancer patients.Results Of the 154 patients,33 had VTE,with an incidence of 21.43%.Compared with non-VTE group,the proportion of diabetes mellitus in VTE group was significantly higher(χ^(2)=5.866,P<0.05).Compared with the non-VTE group,the VTE group had obviously higher levels of serum miR-374a-5p,miR-200c-3p,and SAA4(t=9.143,5.538,6.243,P<0.05).Multivariate Logistic regression results show that diabetes mellitus(OR=1.851),serum miR-374a-5p(OR=1.584),miR-200c-3p(OR=1.519),and SAA4 level(OR=1.627)were risk factors for VTE in elderly patients with lung cancer(P<0.05).ROC curve found that the AUC of serum miR-374a-5p,miR-200c-3p,and SAA4 alone in predicting VTE in elderly lung cancer patients was 0.746,0.770,and 0.748,respectively,with sensitivity of 72.73%,66.67%,and 75.76%,specificity of 83.47%,84.30%,and 82.64%,respectively.The combined prediction of the three factors for VTE in elderly lung cancer patients had an AUC of 0.910,a sensitivity of 87.50%,and a specificity of 80.90%.Conclusion The serum levels of miR-374a-5p,miR-200c-3p,and SAA4 are higher in elderly lung cancer patients with VTE,and the combination of serum miR-374a-5p,miR-200c-3p,and SAA4 has a higher value in predicting VTE in elderly lung cancer patients,which is helpful for clinical prediction.
作者 冯小玲 成军霞 冯艳 FENG Xiaoling;CHENG Junxia;FENG Yan(Department of Respiratory and Critical Care Medicine,Guang′an People′s Hospital,Guang′an 638000,Sichuan,China)
出处 《医学研究与战创伤救治》 北大核心 2025年第8期857-861,共5页 Journal of Medical Research & Combat Trauma Care
关键词 肺癌 静脉血栓 微小RNA-374a-5p 微小RNA-200c-3p 淀粉样蛋白A4 lung cancer venous thrombosis micro RNA-374a-5p micro RNA-200c-3p amyloid protein A4
  • 相关文献

参考文献9

二级参考文献83

  • 1周建西,代俊利,宋冀.Caprini血栓风险评估模型预测肺癌患者深静脉血栓形成风险的有效性研究[J].大连医科大学学报,2020,42(1):21-26. 被引量:27
  • 2Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guide?lines on the diagnosis and management of acute pulmonary embo?lism[J]. Eur Heart J, 2014,35(43):3033-3069.
  • 3Roberts LN, Patel RK, Donaldson N, et al. Post-thrombotic syn?drome is an independent determinant of health-related quality oflife following both first proximal and distal deep vein thrombosis[J]. Haematologica, 2014,99(3):e41-43.
  • 4Wang KL, Chu PH, Lee CH, et al. Management of venous thrombo?embolisms: Part 1. The consensus for deep vein thrombosis[J]. Ac?ta Cardiol Sin, 2016,32(1):1-22.
  • 5Kyrle PA, Eichinger S. Deep vein thrombosis[J]. Lancet, 2005,365(9465):1163-1174.
  • 6Jack L. Cronenwett K. Wayne Johnston. Rutherford’s vascular sur?gery(Eighth edition) [M].Elsvier,2014:745-754.
  • 7Goodacre S, Sampson F, Thomas S, et al. Systematic review andmeta-analysis of the diagnostic accuracy of ultrasonography fordeep vein thrombosis[J]. BMC Med Imaging,2005,5:6.
  • 8Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Anti?thrombotic therapy and prevention of thrombosis, 9th ed: AmericanCollege of Chest Physicians Evidence-Based Clinical PracticeGuidelines[J]. Chest,2012,141(2 Suppl): e351S-418S.
  • 9Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimerin the diagnosis of suspected deep vein thrombosiss[J]. N Engl JMed, 2003,349(13):1227-1235.
  • 10Righini M, Perrier A, De Moerloose P, et al. D-Dimer for venousthromboembolism diagnosis: 20 years later[J]. J Thromb Haemost,2008,6(7):1059-1071.

共引文献450

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部